Orthocell Limited (ASX:OCC)

Market Cap	303.55M
Revenue (ttm)	6.31M
Net Income (ttm)	-3.25M
Shares Out	244.80M
EPS (ttm)	-0.02
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	680,752
Average Volume	462,766
Open	1.255
Previous Close	1.240
Day's Range	1.250 - 1.320
52-Week Range	0.362 - 1.790
Beta	0.20
RSI	46.60
Earnings Date	Aug 29, 2025

About Orthocell

Orthocell Limited, a regenerative medicine company, develops and commercializes cell therapies and biological medical devices for the repair of various bone and soft tissue injuries in Australia, the United States, the United Kingdom, and the European Union. The company offers Ortho-ATI, a cell therapy for treatment of chronic tendon injuries; Striate+, a resorbable collagen membrane used for guided bone and tissue regeneration in dental procedure; Remplir, a collagen scaffold used in peripheral nerve repair; and Ortho-ACI, an autologous chondr...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2006
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: OCC

Financial Performance

In 2024, Orthocell's revenue was 5.32 million, an increase of 25.27% compared to the previous year's 4.24 million. Losses were -7.18 million, 14.9% more than in 2023.